Dedicated to discovery
in fracture fixation
We are engaged in the development of next generation therapeutics in osteoporosis. We have developed a regenerative medicine approach for fragility fractures, improving implant anchorage leading to less fixation failures, re-operations, reduced societal costs and better quality of life.
The concept has been tested and proven in-vitro, in pre-clinical in-vivo studies, and in osteoporotic human bone explants, and is currently undergoing a feasibility study.
We have developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures.
Moroxite F appoints Johan Tinnerholm as the CEO
Moroxite F announces the appointment of Johan Tinnerholm as the CEO. Johan has a broad experience from leading roles at stock listed companies like Agilit Holding AB, Curando Nordic and Safeture.
Moroxite F raises external funding
Moroxite F has raised its first external capital of SEK 10 millon, of which 6 million from Fåhraeus Startup and Growth and 4 million from ALMI Invest.